{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:32:50Z","timestamp":1793165570504,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009408","name":"Fondation Brain Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009408","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007202","name":"Gouvernement du Canada | Instituts de Recherche en Sant\u00e9 du Canada | CIHR Skin Research Training Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008914","name":"Ontario Brain Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health"},{"DOI":"10.13039\/501100006680","name":"Takeda Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006680","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1038\/s41380-024-02523-7","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T09:02:44Z","timestamp":1710838964000},"page":"2459-2466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of olanzapine exposure on relapse and brain structure in patients with major depressive disorder with psychotic features"],"prefix":"10.1038","volume":"29","author":[{"given":"Helena K.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0156-0395","authenticated-orcid":false,"given":"Aristotle N.","family":"Voineskos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8046-0212","authenticated-orcid":false,"given":"Nicholas H.","family":"Neufeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-7001","authenticated-orcid":false,"given":"George S.","family":"Alexopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen S.","family":"Bingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair J.","family":"Flint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Rothschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M.","family":"Whyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0303-6450","authenticated-orcid":false,"given":"Benoit H.","family":"Mulsant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"key":"2523_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-018-0207-1","volume":"17","author":"R Gournellis","year":"2018","unstructured":"Gournellis R, Tournikioti K, Touloumi G, Thomadakis C, Michalopoulou PG, Michopoulos I, et al. Psychotic (delusional) depression and completed suicide: a systematic review and meta-analysis. Ann Gen Psychiatry. 2018;17:39.","journal-title":"Ann Gen Psychiatry"},{"key":"2523_CR2","doi-asserted-by":"publisher","first-page":"486","DOI":"10.4088\/JCP.11r07324","volume":"73","author":"A Farahani","year":"2012","unstructured":"Farahani A, Correll CU. Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry. 2012;73:486\u201396.","journal-title":"J Clin Psychiatry"},{"key":"2523_CR3","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1001\/jama.2019.10517","volume":"322","author":"AJ Flint","year":"2019","unstructured":"Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Alexopoulos GS, Rudorfer MV, et al. Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial. JAMA. 2019;322:622\u201331.","journal-title":"JAMA"},{"key":"2523_CR4","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jamapsychiatry.2020.0036","volume":"77","author":"AN Voineskos","year":"2020","unstructured":"Voineskos AN, Mulsant BH, Dickie EW, Neufeld NH, Rothschild AJ, Whyte EM, et al. Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical Trial. JAMA Psychiatry. 2020;77:674\u201383.","journal-title":"JAMA Psychiatry"},{"key":"2523_CR5","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1111\/bcp.15260","volume":"88","author":"M Ismail","year":"2022","unstructured":"Ismail M, Straubinger T, Uchida H, Graff-Guerrero A, Nakajima S, Suzuki T, et al. MAP Bayesian modelling combining striatal dopamine receptor occupancy and plasma concentrations to optimize antipsychotic dose regimens in individual patients. Br J Clin Pharmacol. 2022;88:3341\u201350.","journal-title":"Br J Clin Pharmacol"},{"key":"2523_CR6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1001\/jamapsychiatry.2014.2178","volume":"72","author":"TA Lesh","year":"2015","unstructured":"Lesh TA, Tanase C, Geib BR, Niendam TA, Yoon JH, Minzenberg MJ, et al. A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia. JAMA Psychiatry. 2015;72:226\u201334.","journal-title":"JAMA Psychiatry"},{"key":"2523_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-38","volume":"13","author":"AJ Flint","year":"2013","unstructured":"Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Mulsant BH, Rudorfer MV, et al. Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD II. BMC Psychiatry. 2013;13:38.","journal-title":"BMC Psychiatry"},{"key":"2523_CR8","unstructured":"APA. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text Revision. Washington, DC: American Psychiatric Association; 2000."},{"key":"2523_CR9","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1001\/archpsyc.1988.01800320058007","volume":"45","author":"JB Williams","year":"1988","unstructured":"Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988;45:742\u20137.","journal-title":"Arch Gen Psychiatry"},{"key":"2523_CR10","doi-asserted-by":"crossref","unstructured":"Spitzer R, Endicott J. Schedule for affective disorders and schizophrenia. 3 ed. New York, NY: New York State Psychiatric Institute: Biometrics Research; 1979.","DOI":"10.1037\/t07870-000"},{"key":"2523_CR11","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/j.1365-2753.2007.00921.x","volume":"14","author":"M Berk","year":"2008","unstructured":"Berk M, Ng F, Dodd S, Callaly T, Campbell S, Bernardo M, et al. The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use. J Eval Clin Pract. 2008;14:979\u201383.","journal-title":"J Eval Clin Pract"},{"key":"2523_CR12","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.biopsych.2006.05.033","volume":"60","author":"BS Meyers","year":"2006","unstructured":"Meyers BS, English J, Gabriele M, Peasley-Miklus C, Heo M, Flint AJ, et al. A delusion assessment scale for psychotic major depression: Reliability, validity, and utility. Biol Psychiatry. 2006;60:1336\u201342.","journal-title":"Biol Psychiatry"},{"key":"2523_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1017\/S1041610204000390","volume":"16","author":"AF Jorm","year":"2004","unstructured":"Jorm AF. The Informant Questionnaire on cognitive decline in the elderly (IQCODE): a review. Int Psychogeriatr. 2004;16:275\u201393.","journal-title":"Int Psychogeriatr"},{"key":"2523_CR14","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s40262-015-0275-1","volume":"54","author":"SJ Davies","year":"2015","unstructured":"Davies SJ, Mulsant BH, Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, et al. The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD. Clin Pharmacokinet. 2015;54:1161\u20138.","journal-title":"Clin Pharmacokinet"},{"key":"2523_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/0091270007310385","volume":"48","author":"KL Bigos","year":"2008","unstructured":"Bigos KL, Pollock BG, Coley KC, Miller DD, Marder SR, Aravagiri M, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 2008;48:157\u201365.","journal-title":"J Clin Pharmacol"},{"key":"2523_CR16","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/JCP.0b013e3182979a0a","volume":"33","author":"S Moriguchi","year":"2013","unstructured":"Moriguchi S, Bies RR, Remington G, Suzuki T, Mamo DC, Watanabe K, et al. Estimated dopamine D(2) receptor occupancy and remission in schizophrenia: analysis of the CATIE data. J Clin Psychopharmacol. 2013;33:682\u20135.","journal-title":"J Clin Psychopharmacol"},{"key":"2523_CR17","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.2196\/resprot.9682","volume":"7","author":"T Sumiyoshi","year":"2018","unstructured":"Sumiyoshi T, Watanabe K, Noto S, Sakamoto S, Moriguchi Y, Okamoto S. Prospective Epidemiological Research on Functioning Outcomes Related to Major Depressive Disorder in Japan (PERFORM-J): Protocol for a Prospective Cohort Study. JMIR Res Protoc. 2018;7:e161.","journal-title":"JMIR Res Protoc"},{"key":"2523_CR18","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1001\/archpsyc.60.6.585","volume":"60","author":"BC Ho","year":"2003","unstructured":"Ho BC, Andreasen NC, Nopoulos P, Arndt S, Magnotta V, Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry. 2003;60:585\u201394.","journal-title":"Arch Gen Psychiatry"},{"key":"2523_CR19","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1176\/appi.ajp.2007.05111903","volume":"164","author":"BC Ho","year":"2007","unstructured":"Ho BC, Andreasen NC, Dawson JD, Wassink TH. Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia. Am J Psychiatry. 2007;164:1890\u20139.","journal-title":"Am J Psychiatry"},{"key":"2523_CR20","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.biopsych.2010.11.010","volume":"69","author":"AC Vernon","year":"2011","unstructured":"Vernon AC, Natesan S, Modo M, Kapur S. Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol Psychiatry. 2011;69:936\u201344.","journal-title":"Biol Psychiatry"},{"key":"2523_CR21","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/sj.npp.1301233","volume":"32","author":"GT Konopaske","year":"2007","unstructured":"Konopaske GT, Dorph-Petersen KA, Pierri JN, Wu Q, Sampson AR, Lewis DA. Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacology. 2007;32:1216\u201323.","journal-title":"Neuropsychopharmacology"},{"key":"2523_CR22","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.biopsych.2007.08.018","volume":"63","author":"GT Konopaske","year":"2008","unstructured":"Konopaske GT, Dorph-Petersen KA, Sweet RA, Pierri JN, Zhang W, Sampson AR, et al. Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol Psychiatry. 2008;63:759\u201365.","journal-title":"Biol Psychiatry"},{"key":"2523_CR23","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/mp.2011.38","volume":"16","author":"KL Bigos","year":"2011","unstructured":"Bigos KL, Bies RR, Pollock BG, Lowy JJ, Zhang F, Weinberger DR. Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Mol Psychiatry. 2011;16:620\u20135.","journal-title":"Mol Psychiatry"},{"key":"2523_CR24","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1212\/WNL.0b013e318230a16c","volume":"77","author":"AS Fleisher","year":"2011","unstructured":"Fleisher AS, Truran D, Mai JT, Langbaum JB, Aisen PS, Cummings JL, et al. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology. 2011;77:1263\u201371.","journal-title":"Neurology"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02523-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02523-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02523-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T08:09:23Z","timestamp":1726733363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02523-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2523"],"URL":"https:\/\/doi.org\/10.1038\/s41380-024-02523-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3254016\/v1","asserted-by":"object"}]},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,19]]},"assertion":[{"value":"10 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HKK has no financial relationships with commercial interests. ANV receives funding from the National Institute of Mental Health (NIMH), Canadian Institutes of Health Research, Canada Foundation for Innovation, Centre for Addiction and Mental Health (CAMH) Foundation, and the University of Toronto. NHN receives grant support from the Canadian Institutes of Health Research, Physicians\u2019 Services Incorporated Foundation, and the University of Toronto. GA has served on an advisory board of Otsuka and has been on the speakers bureau of Otsuka. KSB receives grant support from the University of Toronto. AJF has received grant support from the US National Institutes of Health, the Patient-Centered Outcomes Research Institute, the Canadian Institutes of Health Research, Brain Canada, the Ontario Brain Institute, and Alzheimer\u2019s Association. PM has no financial relationships with commercial interests. AJR has received grant or research support from Janssen, Otsuka, and the Irving S. and Betty Brudnick Endowed Chair in Psychiatry; is a consultant to Daiichi Sankyo, Inc, Sage Therapeutics, Xenon Pharmaceuticals, Lupin Pharmaceuticals, Zydus Pharmaceuticals (USA), Inc., and Neumora Therapeutics; and has received royalties for the Rothschild Scale for Antidepressant Tachyphylaxis (RSAT)\u00ae, Clinical Manual for the Diagnosis and Treatment of Psychotic Depression, American Psychiatric Press, 2009; The Evidence-Based Guide to Antipsychotic Medications, American Psychiatric Press, 2010; The Evidence-Based Guide to Antidepressant Medications, American Psychiatric Press, 2012, and from UpToDate\u00ae. EMW receives grant support from the NIMH and Health Resources and Services Administration. Dr. Mulsant holds and receives support from the Labatt Family Chair in Biology of Depression in Late-Life Adults at the University of Toronto. He currently receives or has received research support from Brain Canada, the CAMH Foundation, the Canadian Institutes of Health Research, and the US National Institutes of Health (NIH); research support from Bristol-Myers Squibb (medications for an NIH-funded clinical trial), Eli-Lilly (medications for an NIH-funded clinical trial), Pfizer (medications for an NIH-funded clinical trial), Capital Solution Design LLC (software used in a study funded by CAMH Foundation), and HAPPYneuron (software used in a study funded by Brain Canada).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}